Project Grant R41AI195081
Award Date 9/18/25
Completion Date 8/31/26
Dollars Obligated $314K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Austin, TX 78750, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $1,000,000 Project Grant to Vast Therapeutics, Inc. The grant, effective from September 11, 2025 to August 31, 2027, will support the development of a novel nitric oxide-releasing formulation, ALX1, as a treatment for difficult non-tuberculous mycobacterial lung infections. The project aims to evaluate the pharmacokinetics and...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $298,829 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Tarn Biosciences, Inc. to develop novel nitroreductase-activated inhibitor compounds as treatments for tuberculosis (TB) and nontuberculous mycobacterial (NTM) infections. The funding, awarded on August 21, 2025, supports the discovery and preclinical development of a lead candidate compound, HC2210, which has shown...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded Vast Therapeutics, Inc. a $2,000,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a novel nitric oxide-releasing formulation (ALX1) for the treatment of Pseudomonas aeruginosa infections in bronchiectasis patients. The objective is to answer critical questions needed to initiate Phase II proof-of-concept clinical trials for this broad-spectrum antibacterial therapy,...
- This federal Project Grant award of $300,001 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research by Fimbrion Therapeutics Inc. to develop novel small molecule drugs targeting the respiratory protein QcrB in mycobacteria. The goal is to create new antimicrobial therapies to treat infections caused by non-tuberculous mycobacteria (NTM), which are highly resistant to existing antibiotics...
- This Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), is focused on the development of novel benzyl-piperidine antifungal agents to treat intractable Mucorales infections. The $299,946 award to Microbiotix, Inc., a clinical-stage biopharmaceutical company in Worcester, MA, aims to chemically optimize a lead series of benzyl-piperidine compounds to improve their...
- This $314,363 Project Grant was awarded on September 11, 2025 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research grant program (CFDA 93.855) to Via Therapeutics, LLC, a for-profit company based in Austin, Texas. The grant supports the development of a microneedle-based mRNA flu vaccine for transcutaneous immunization. The goal is to create a stable, patient-friendly influenza vaccine delivered through the skin rather than by...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $300,000 in funding to Fimbrion Therapeutics Inc. in Missouri to develop an orally bioavailable thiazolino-pyridone (TZP) small molecule series with inhibitory activity against Mycobacterium tuberculosis. The goal is to create a first-in-class TZP compound that could become a novel drug for treating...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $2,248,740 Project Grant through the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) to Michigan State University on July 7, 2025. The grant supports the development of a new series of nitrofuran compounds that are potent inhibitors against Mycobacterium tuberculosis (MTB) and Mycobacterium abscessus (MAB), the bacteria that cause tuberculosis and non-tuberculous mycobacterial infections,...
- This $1,378,102 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), to Health Research, Inc. at its Wadsworth Center Division. The grant supports research to develop the therapeutic potential of a mycobacteriophage lysin, LysB, as a broad-spectrum adjunct treatment for Mycobacterium abscessus (MAB) infections, which are life-threatening for people with certain...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $292,746 Cooperative Agreement to Tsrl, Inc. (doing business as Therapeutic Systems Research Laboratories), a woman-owned small business located in Ann Arbor, Michigan. The purpose of this award is to conduct a Phase 1 clinical trial to assess the pharmacokinetics, safety, and tolerance of a zanamivir transdermal system in healthy subjects. This...